Exact Sciences Corp.

EXAS

$104.50

+38.7% (1 year change)

Avg closing price

Price range

Market Cap

$18.5 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$70.75 - $159.54

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-23.94x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $18.5 Billion
Enterprise Value $18.3 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +38.7%
52-Week High $159.54
52-Week Low $70.75
Beta 0.78
Outstanding Shares 172 Million
Avg 30 Day Volume 1.23 Million

Valuation

P/E Ratio -23.94
PEG -5.4
Earnings per Share -$4.95
Price to Sales Ratio 14.93
Price to Book Ratio 6.53
Revenue to Enterprise Value 13.85
EBIT to Enterprise Value -69.59
Total Debt to Enterprise Value 0.09
Debt to Equity 0.57

Profitability

Revenue $1.32 Billion
Gross Profit $997 Million
EBIT -$263 Million
Net Income -$334 Million
Profit Margin -25.27%
Quarterly Earnings Growth (YoY) +443.5%
Return on Equity -11.82%
Return on Assets -6.78%
Return on Invested Capital -6.04%

News

Exact Sciences Drops on Earnings Loss, Lack of Visibility

Exact Sciences Drops on Earnings Loss, Lack of Visibility

Exact Sciences swung to a large fourth quarter loss due in part to its purchase of Base Genomics.

The Street The Street, 3 months ago
Exact Sciences Announces Fourth Quarter 2020 Results

Exact Sciences Announces Fourth Quarter 2020 Results

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and ...

PR Newswire PR Newswire, 3 months ago
Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com

Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com

Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp.

Investing.com Investing.com, 4 months ago